Safety of Proton Pump Inhibitors in GORD

TASK OBJECTIVE: To evaluate the efficacy and safety of proton pump inhibitors (PPIs) in the treatment of gastroesophageal reflux disease (GORD) in infants up to 12 months.
DATA SOURCES: Conducted through PubMed. Reference citations from identified articles were also reviewed.
STUDY SELECTION AND DATA EXTRACTION: All double-blind,placebo-controlled trials published in English that evaluated the safety and efficacy of PPIs in infants with GERD were included in this review. Trials involving children older than 12 months were not included.
DATA SYNTHESIS: GERD is a source of pain and discomfort in adults; yet, in infants, symptoms that are thought to be indicative of painful stimuli have no clear cause-and-effect relationship with infant GERD. PPIs are beneficial in relieving symptoms of GERD in the adult population,but their usefulness in decreasing GERD-associated behaviors in infants is still questionable, despite a large increase in PPI prescribing for children <1 year of age. In all studies reviewed, infants treated with PPIs did not experience a significant decrease in behaviors perceived to be caused by GERD. The largest placebo-controlled trial to date found that rates of adverse events were increased in the PPI group compared with the placebo group, whereas the other trials reviewed reported no difference in adverse effects with the use of PPIs.
CONCLUSIONS: Clinical trials reveal that PPI therapy is not an effective treatment for common infant GORD associated symptoms. Evidence supporting safety of PPI use in infants is conflicting, and more large-scale, randomized, placebo-controlled trials are necessary to better establish the role of PPIs in infant GORD.
Resident, Idaho Drug Information Service, College of Pharmacy, Idaho State University, 921 S. 8th Ave., Stop 8092, Pocatello, ID 83209, fax 208/282-3003,

About Author


As well as being one of the founding members of refluxSUPPORT...Jonathan is a Board Member and trustee of Living with Reflux – the only UK Charity for infants with reflux related conditions.He is also a stakeholder in the National Institute for Health and Care Excellence (NICE) – Gastro-oesophageal reflux in children and young people.He has three daughters of which the eldest is now seventeen. Two suffered from severe reflux.